Skip to Main Content

Author Details

Victoria M Richon
Discovery and Preclinical Sciences
1984
118
73
PMIDPaper TitleJournal TitlePublished Year
34375612PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity.Cancer Cell2021
33705687A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants.Cell Chem Biol2021
34375612PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity.Cancer Cell2021
33705687A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants.Cell Chem Biol2021
28950000Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.PLoS One2017
28950000Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.PLoS One2017
26769278The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.J Med Chem2016
26769278The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.J Med Chem2016
25979925CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy.Clin Cancer Res2015
25897982Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.Antioxid Redox Signal2015
26222556Structural Approaches to Cancer Drug Development.N Engl J Med2015
25979925CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy.Clin Cancer Res2015
26222556Structural Approaches to Cancer Drug Development.N Engl J Med2015
25897982Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.Antioxid Redox Signal2015
24415392Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.Biopharm Drug Dispos2014
24415392Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.Biopharm Drug Dispos2014
24563539Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.Mol Cancer Ther2014
24563539Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.Mol Cancer Ther2014
23138183Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.Leukemia2013
23801631Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.Blood2013
24092806Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.Mol Cancer Ther2013
24319157Drug discovery in rare indications: opportunities and challenges.Hematology Am Soc Hematol Educ Program2013
23361907Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.Blood2013
23138183Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.Leukemia2013
23620515Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.Proc Natl Acad Sci U S A2013
23160372Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics.Oncogene2013
24319157Drug discovery in rare indications: opportunities and challenges.Hematology Am Soc Hematol Educ Program2013
24092806Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.Mol Cancer Ther2013
23620515Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.Proc Natl Acad Sci U S A2013
23801631Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.Blood2013
23160372Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics.Oncogene2013
23361907Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.Blood2013
22850114A687V EZH2 is a gain-of-function mutation found in lymphoma patients.FEBS Lett2012
22850114A687V EZH2 is a gain-of-function mutation found in lymphoma patients.FEBS Lett2012
22978415Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L.Chem Biol Drug Des2012
23023262A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.Nat Chem Biol2012
23023262A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.Nat Chem Biol2012
22978415Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L.Chem Biol Drug Des2012
21118801Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.J Biol Chem2011
21118801Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.J Biol Chem2011
21493594PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models.Cancer Res2011
21564555Chemogenetic analysis of human protein methyltransferases.Chem Biol Drug Des2011
21741597MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.Cancer Cell2011
21741596Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.Cancer Cell2011
21856302The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states.FEBS Lett2011
21856302The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states.FEBS Lett2011
21564555Chemogenetic analysis of human protein methyltransferases.Chem Biol Drug Des2011
21741597MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.Cancer Cell2011
21741596Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.Cancer Cell2011
21493594PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models.Cancer Res2011
  • 1 - 50 of 236

Recommended Authors

Jun Qi
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 7
No??l J-M Raynal
Sainte-Justine University Hospital Research Center
Career Start Year 2005
Number of shared co-authors 1
Anderly C Chueh
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 0
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 2
Helai P Mohammad
Collegeville
Career Start Year 2003
Number of shared co-authors 1
Stefan Kubicek
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
Career Start Year 2003
Number of shared co-authors 1
John Connelly
Institute of Genetics and Cancer, University of Edinburgh
Career Start Year 2000
Number of shared co-authors 2
Rose Hurren
Princess Margaret Cancer Centre
Career Start Year 1999
Number of shared co-authors 0
Andr?? S Bachmann
College of Human Medicine, Michigan State University
Career Start Year 1998
Number of shared co-authors 0
Christian A Hassig
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 1994
Number of shared co-authors 0
Kristina A Cole
Perelman School of Medicine, University of Pennsylvania
Career Start Year 1994
Number of shared co-authors 1
Olaf Witt
Hopp Children's Cancer Center Heidelberg (KiTZ)
Career Start Year 1993
Number of shared co-authors 0
Janine Arts
Institute for Molecules and Materials (IMM), Radboud University
Career Start Year 1992
Number of shared co-authors 1
Linda Z Penn
University of Toronto
Career Start Year 1990
Number of shared co-authors 0
Glenn M Marshall
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year 1989
Number of shared co-authors 3
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 1
David S Schrump
Center for Cancer Research, National Cancer Institute
Career Start Year 1988
Number of shared co-authors 7
Kristian Helin
The Institute of Cancer Research
Career Start Year 1988
Number of shared co-authors 2
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 4
Rakesh Kumar
Rutgers New Jersey Medical School
Career Start Year 1987
Number of shared co-authors 2
Chi V Dang
Johns Hopkins University School of Medicine
Career Start Year 1978
Number of shared co-authors 2
Robert H Shoemaker
National Cancer Institute
Career Start Year 1978
Number of shared co-authors 3
Scott H Kaufmann
Mayo Clinic
Career Start Year 1977
Number of shared co-authors 1
Anne Monks
Institute of Biomedical Engineering (IBME), University of Oxford
Career Start Year 1976
Number of shared co-authors 3
Charles Patrick Reynolds
Cancer Center, Texas Tech University Health Sciences Center
Career Start Year 1975
Number of shared co-authors 2
Paul Workman
The Institute of Cancer Research
Career Start Year 1974
Number of shared co-authors 0
Michelle Haber
School of Clinical Medicine
Career Start Year 1973
Number of shared co-authors 3
Peter J Houghton
The University of Texas Health Science Center at San Antonio
Career Start Year 1971
Number of shared co-authors 4
John N Weinstein
The University of Texas MD Anderson Cancer Center
Career Start Year 1968
Number of shared co-authors 6
Stephen B Baylin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Career Start Year 1963
Number of shared co-authors 3

Collaborators

J Paul Secrist
Oncology R&D
Co-authored papers 7
John F Reilly
Goldfinch Bio Inc.
Co-authored papers 6
Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
Scott A Armstrong
Boston Children's Hospital
Co-authored papers 4
Andrey Loboda
Merck & Co., Inc.
Co-authored papers 3
Ricky W Johnstone
The University of Melbourne
Co-authored papers 3
David S Siegel
Co-authored papers 2
Kenneth C Anderson
Dana Farber Cancer Institute
Co-authored papers 2
Purva Bali
Co-authored papers 2
Aniruddha J Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 2
Andrea Newbold
Peter MacCallum Cancer Centre
Co-authored papers 2
Ronald C Hendrickson
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Lin Leng
Yale University School of Medicine
Co-authored papers 2
Guillermo Garcia-Manero
MD Anderson Cancer Center
Co-authored papers 2
Amit U Sinha
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Mario Niepel
Co-authored papers 2
Yonghong Xiao
TESARO Inc.
Co-authored papers 2
Kunal S Taskar
Drug Metabolism and Pharmacokinetics
Co-authored papers 1
Julie L Bronder
Center for Cancer Training, National Cancer Institute, National Institutes of Health
Co-authored papers 1
Leigh Ellis
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 1
Jeanne M Herring
Program Resources Inc. NCI-FCDRC
Co-authored papers 1
Maciej Wiznerowicz
Co-authored papers 1
Keith Elliston
tranSMART Foundation
Co-authored papers 1
Robert L Walker
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 1
Julie A Gaasch
Co-authored papers 1
Leslie M Thompson
Co-authored papers 1
Nikola P Pavletich
Memorial Sloan Kettering Cancer Center
Co-authored papers 1
Lionel Feigenbaum
Science Applications International Corporation/Frederick
Co-authored papers 1
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Jorge Cortes
Georgia Cancer Center
Co-authored papers 1
Release 1.2